Research programme: siRNA therapeutics - Silence Therapeutics

Drug Profile

Research programme: siRNA therapeutics - Silence Therapeutics

Alternative Names: Atu014; Atu093; Atu111; Atu134; Atu150; Atu195; AtuRNAi

Latest Information Update: 17 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Atugen AG
  • Developer Charite of Berlin; McGill University; Sanofi; Silence Therapeutics; Silence Therapeutics plc
  • Class Small interfering RNA
  • Mechanism of Action Endothelin A receptor antagonists; Protein kinase N3 inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute lung injury; Solid tumours

Highest Development Phases

  • Preclinical Acute lung injury; Pulmonary arterial hypertension
  • Discontinued Diabetes mellitus; Solid tumours; Wounds

Most Recent Events

  • 12 Apr 2016 Discontinued - Preclinical for Solid tumours in Germany (Parenteral) (Silence Therapeutics pipeline, April 2016)
  • 12 Apr 2016 Preclinical trials in Pulmonary arterial hypertension in England (Parenteral) (Silence Therapeutics pipeline, April 2016)
  • 19 Jun 2014 Dainippon Sumitomo Pharma is now called Sumitomo Dainippon Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top